{"id":7225,"date":"2024-08-13T14:01:34","date_gmt":"2024-08-13T07:01:34","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=7225"},"modified":"2024-08-13T14:01:34","modified_gmt":"2024-08-13T07:01:34","slug":"australian-biotech-incubator-proto-axiom-announces-20m-series-b-first-close","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=7225","title":{"rendered":"Australian biotech incubator Proto Axiom announces $20M Series B first close"},"content":{"rendered":"

$20M<\/span> unlocked for opportunities in Australian biotech innovation, valuing Proto Axiom at $90M<\/span> <\/p>\n

SYDNEY<\/span><\/span>, Aug. 13, 2024<\/span><\/span> \/PRNewswire\/ — Proto Axiom, the Australian biomedical technology incubator has today announced a $20 million<\/span> first close of its targeted $30 million<\/span> Series B, to bolster Australia’s<\/span> biotechnology (biotech) sector through increased intellectual property (IP) retention. The Series B first close and $15M<\/span> Series A announced in September 2022<\/span> gives Proto Axiom a cash value of $90 million<\/span>.<\/p>\n

Series B investors join the significant institutional support Proto Axiom received in its Series A from investors such as Catalio<\/a>, Parkview International<\/a>, Churchill Asset Management<\/a> and HOF Capital<\/a>.<\/p>\n

“This support from major private and institutional investors will ensure Proto Axiom can continue constructing a leading portfolio of the most innovative new businesses in biotechnology, while onshoring Australia’s<\/span> scientific capacity to keep IP in Australia<\/span>,” Proto Axiom CEO, Anthony Liveris<\/span>, said.<\/p>\n

“Australia<\/span> produces world-class intellectual property in drug development and medical equipment, but inadequately capitalises on the downstream economics and associated job multipliers.<\/p>\n

Through the capital unlocked in the Series B first close, Proto Axiom will continue strategically investing and supporting the development of Australia’s<\/span> best science,” Liveris said.<\/p>\n

Proto Axiom distinguishes itself from traditional funds by operating as a holistic enterprise to onshore sovereign capacity through a comprehensive partnership model, covering technical oversight, administrative support, future financing, and hands-on research assistance.<\/p>\n

Liveris said this new funding would allow Proto Axiom to continue investing in projects like University of New South Wales’<\/span> spin-out, Swan Genomics.<\/p>\n

Proto recently led the funding round and invested $2 million<\/span> in Swan, a cutting-edge new technology for rapid, highly accurate long-read, low copy number DNA sequencing, using a highly innovative Plasmonic Nanoantenna based approach.<\/p>\n

“Also, one of Proto’s earliest investments, Endo\u00a0Axiom, has continued to go from strength to strength, and we look forward to the program entering first-in-human trials,” Liveris added. Endo Axiom has a platform technology for the oral delivery of insulin to treat Type 1 Diabetes, which would enable needle-free insulin delivery for patients, including children.<\/p>\n

About Proto Axiom
Proto Axiom is Australia’s<\/span> first true biotech incubator, dedicated to nurturing and accelerating the growth of early-stage biotech ventures. By providing essential resources, mentorship, and funding, Proto Axiom aims to transform innovative ideas into successful biotech solutions that address global health challenges. Our hands-on approach to support Australian research is a first-in-country model.<\/p>\n

Proto Axiom is hosting the Challenger Summit<\/a> in Sydney<\/span> on 16 October 2024<\/span>, which will provide a platform for researchers to showcase their innovative biotech solutions, competing for over $250,000<\/span> in unencumbered grant financing. Recently announced panellists include Gavin MacLaren<\/span>, CEO, Corrs Chamber Westgarth, Dr. Larry Marshall<\/span>, Former CEO, CSIRO, Reed Jobs<\/span>, Investor, Yosemite, and Dr. Mehmood Khan<\/span>, CEO, Hevolution.<\/p>\n

Media Contact:
William Pretty<\/span> (Teneo)
E: william.pretty@teneo.com<\/a>
M: +61 405 197 970\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

$20M<\/span> unlocked for opportunities in Australian biotech innovation, valuing Proto Axiom at $90M<\/span> <\/p>\n

SYDNEY<\/span><\/span>, Aug. 13, 2024<\/span><\/span> \/PRNewswire\/ — Proto Axiom, the Australian biomedical technology incubator has today announced a $20 million<\/span> first close of its targeted $30 million<\/span> Series B, to bolster Australia’s<\/span> biotechnology (biotech) sector through increased intellectual property (IP) retention. The Series B first close and $15M<\/span> Series A announced in September 2022<\/span> gives Proto Axiom a cash value of $90 million<\/span>.<\/p>\n

Series B investors join the significant institutional support Proto Axiom received in its Series A from investors such as Catalio<\/a>, Parkview International<\/a>, Churchill Asset Management<\/a> and HOF Capital<\/a>.<\/p>\n

“This support from major private and institutional investors will ensure Proto Axiom can continue constructing a leading portfolio of the most innovative new businesses in biotechnology, while onshoring Australia’s<\/span> scientific capacity to keep IP in Australia<\/span>,” Proto Axiom CEO, Anthony Liveris<\/span>, said.<\/p>\n

“Australia<\/span> produces world-class intellectual property in drug development and medical equipment, but inadequately capitalises on the downstream economics and associated job multipliers.<\/p>\n

Through the capital unlocked in the Series B first close, Proto Axiom will continue strategically investing and supporting the development of Australia’s<\/span> best science,” Liveris said.<\/p>\n

Proto Axiom distinguishes itself from traditional funds by operating as a holistic enterprise to onshore sovereign capacity through a comprehensive partnership model, covering technical oversight, administrative support, future financing, and hands-on research assistance.<\/p>\n

Liveris said this new funding would allow Proto Axiom to continue investing in projects like University of New South Wales’<\/span> spin-out, Swan Genomics.<\/p>\n

Proto recently led the funding round and invested $2 million<\/span> in Swan, a cutting-edge new technology for rapid, highly accurate long-read, low copy number DNA sequencing, using a highly innovative Plasmonic Nanoantenna based approach.<\/p>\n

“Also, one of Proto’s earliest investments, Endo\u00a0Axiom, has continued to go from strength to strength, and we look forward to the program entering first-in-human trials,” Liveris added. Endo Axiom has a platform technology for the oral delivery of insulin to treat Type 1 Diabetes, which would enable needle-free insulin delivery for patients, including children.<\/p>\n

About Proto Axiom
Proto Axiom is Australia’s<\/span> first true biotech incubator, dedicated to nurturing and accelerating the growth of early-stage biotech ventures. By providing essential resources, mentorship, and funding, Proto Axiom aims to transform innovative ideas into successful biotech solutions that address global health challenges. Our hands-on approach to support Australian research is a first-in-country model.<\/p>\n

Proto Axiom is hosting the Challenger Summit<\/a> in Sydney<\/span> on 16 October 2024<\/span>, which will provide a platform for researchers to showcase their innovative biotech solutions, competing for over $250,000<\/span> in unencumbered grant financing. Recently announced panellists include Gavin MacLaren<\/span>, CEO, Corrs Chamber Westgarth, Dr. Larry Marshall<\/span>, Former CEO, CSIRO, Reed Jobs<\/span>, Investor, Yosemite, and Dr. Mehmood Khan<\/span>, CEO, Hevolution.<\/p>\n

Media Contact:
William Pretty<\/span> (Teneo)
E: william.pretty@teneo.com<\/a>
M: +61 405 197 970\u00a0<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-7225","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/7225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7225"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/7225\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}